We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Avandia Survives Scrutiny From FDA Panel

Law360 (July 31, 2007, 12:00 AM EDT) -- After a contentious day of hearings, a panel of U.S. Food and Drug Administration advisers has overwhelmingly voted to keep Avandia on the market despite data that suggests the controversial diabetes drug leads to more cardiovascular risks.

On Tuesday, the FDA panel voted 22 to 1 to recommend that GlaxoSmithKline's Avandia remain on the market, setting aside widespread outcry from consumers and medical professionals that the medication is unsafe.

While the panel acknowledged that evidence did show an increased risk of heart attack in some Avandia...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.